The company operates a textile processing facility in Ahmedabad, providing dyeing and printing services for cotton fabrics to domestic and export-oriented clients, while also managing a portfolio of financial investments.
The company lacks a durable competitive advantage, as evidenced by low average ROE and ROCE. It operates in a highly fragmented textile processing industry where it functions as a price-taking service provider with limited differentiation.
Management has prioritized returning capital through consistent small dividends and a significant share buyback in 2024. However, substantial capital remains tied up in low-yielding financial investments and associate companies rather than high-return business expansion.
Five years out, the company has stagnated into a value trap as the textile processing division's weak pricing power succumbed to rising input costs and regional competition. The capital that should have been used for modernization was instead locked in opaque, unquoted financial investments and associate companies that failed to yield a return above the cost of capital. As the promoter family continued to draw high remuneration despite flat earnings, minority shareholders realized the business was being run as a private fiefdom for the managers rather than a compounding machine for the owners, leading to a permanent de-rating of the stock.
RichFakir rates Weizmann Ltd's business quality as mediocre — 41/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Weizmann Ltd is trading about 12% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Weizmann Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Weizmann Ltd's fair value is about ₹60 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →